Member Info for Laura2022

That's great then

World destruction versus a better oil price

Priorities

Jamrock

Only just got my head around charts but the RSIfor SND is absolutely rock bottom..

Can't go any lower ...this suggests the move up should commence

What alot of got in common is companies that have needed £5-10mlm per year just to tread water and /or BOD/II holding significant clout and using the "UK market excuse to commit day light robbery l eg Griffiths and 1 other ii holding 60% of REDX and shafting the P.Is

Apparnelty someone called Woodford also tried and failed to do this

As for GGP

At one brief glance that is different as below

During the period, Greatland continued to advance its preparations for a proposed cross-listing on the ASX, with significant progress made. In September 2023, having regard to the listing timetable and activities and opportunities for the business, Greatland decided to defer the ASX cross-listing until 2024. Greatland continues to assess the opportunity to list on the ASX at the appropriate time and is well positioned by the work undertaken to efficiently resume and complete the ASX listing proces

Great summary...the efrect that Perpetual and CRUX had one the share price was magnified due to the fact that out of the 80mln shares in issue they held essentially 12% BUT effectively was about 25% of the free float (because CEO has 44% etc

the original link was when i was looking at an article on immunology on the sar discussion group.

as an aside, i think trench123 said we still have an agreement with sar (or had that now completed?)

https://www.fiercebiotech.com/medtech/roche-picks-prenosis-newly-cleared-sepsis-ai-tool-distribution?itm_source=p****ly-api

This may not be relevant at all but thought it was interesting regarding what Ant said about the potential value of PYC/Doseme A.I tool

The ImmunoScore AI works with electronic health records to digest 22 pieces of clinical information and assigns a patient a risk level linked to the possibility of developing sepsis complications. (JazzIRT/GettyImage)

Following last week’s de novo clearance for the artificial intelligence program, Roche has stepped up to distribute Prenosis’ sepsis risk prediction tool through its diagnostic platforms.

The startup’s ImmunoScore software will be made available to hospital labs and emergency departments through Roche’s navify Algorithm Suite. The financial details of the agreement were not disclosed.

Don't know if you saw this, those was posted about 2 weeks ago :

Neuralink could be one of the

interested parties circling  embattled British chip maker Sondrel. Recently it is believed  that Sondrel solved some of Neuralink problems with their recent human brain implant which other chip suppliers could not solve. Neuralink Corp. is an American neurotechnology company that is developing implantable brain–computer interfaces, based in  California and  founded by Elon Musk and a team of scientists and engineers.

Neuralink had recently livestreamed its first patient implanted with a chip playing online chess.

By way of context, Sondrel is one of only  a handful of firms capable of supplying the higher-spec chips required, others are in Asia but are  considered vulnerable to Chinese interference.

Excellent summary

In similar situations MEN has done x 4 (i have now sold) and REDX x 2 ( I hold)

I believe SND can easily get to 10p-15p particularly now that CRUX asset mgmt are now out and the resulting bounce back was evident to be starting on Friday

For first time in 2 weeks there was buy limits in place into the close

Courtesy of someone on the SND board

However, rumours surfacing last week in the City indicated urgent regulatory modifications being fast-tracked by the UK financial watchdog to stem the exodus and enhance the country’s appeal for business and investment. So it’s worth watching this space.

https://www.ccn.com/news/business/wall-stree-stock-exchange-undervaluation/

Thankyou Smart Money

I agree and sorry its fallen so much for previous holders

What REDX, C4XD SND etc had I common was the fact that

1) they were needing £10mln+ per annum of funding

2) had BOD and /or II holding majority of shares which left private investors at the bottom of the heap

3) funding on this scale (last 5yrs) with no sign of profits/breakeven was unlikely yo be indefinite

But I agree, the SND story is far from over

Yes OTP

The cash flow difficulties have been well documented BUT here at £2 5mln and with the parasitic ROX offering g to fund at 10pence but then triggers the takeover code the surely 10pnis the floor

The main cause of the drop was that with very few shares in issue and 44% held by the CEO who supports the ROX move it means that ehe CRUX sold their whole 8%it had a disproportionate effect, combined with other sellers since the March 28th announcement

CRUX finished selling on Thursday with a large after hours £110k sell, myself and Rocket both believe those shares have gone to another entity

Also about 2 weeks ago In one day there was 15% of the shares traded and yet no TR1

Thanks onetimepost

With SND having Tesla as it's client and with SND helping Elon Musks Neuralink company in Feb it surely puts them in the frame too ?

Thankyou Phrontsist

Who are ARM please ?

Very much q buying opportunities as they are being funded at 10p by the long term funder BUT in 6mths they will then vote to stay listed or go private

All explained in the March 28th RNS

Hope that helps

In similar situation MEN has done 4p to22p and REDX 4p to 9p

Not sure your question Onions ?

That's not what is happening.

It's all in the 28th March update

As was the case yesterday and this morning the maximum availability is just £2200

Hello hopist

And add to the fact its one of only a few stocks that INCREASED revenues in H1 + expected to hit £900,000 income for year ended June and pipeline of contracts now worth £1.5mln (the same as the current market value !)

Also read some of Ant123 posts,PYC seem to be at cutting edge of precision medicine

Interested parties circling  embattled British chip maker Sondrel. Recently it is believed  that Sondrel solved some of Neuralink problems with their recent human brain implant which other chip suppliers could not solve. Neuralink Corp. is an American neurotechnology company that is developing implantable brain–computer interfaces, based in  California and  founded by Elon Musk and a team of scientists and engineers.

Neuralink had recently livestreamed its first patient implanted with a chip playing online chess.

By way of context, Sondrel is one of only  a handful of firms capable of supplying the higher-spec chips required, others are in Asia but are  considered vulnerable to Chinese interference

Flying higher

I agree